Literature DB >> 20537910

Intrahepatic collateral recanalization in symptomatic Budd-Chiari syndrome: a single-center experience.

Thomas Mammen1, Shyamkumar Keshava, C E Eapen, Vinu Moses, N R S Surendra Babu, George Kurien, George Chandy.   

Abstract

The authors present a single-institutional experience with intrahepatic collateral vessel recanalization as a treatment option in symptomatic Budd-Chiari syndrome (BCS). Over a period of 26 months, this procedure was performed in four symptomatic patients in whom standard hepatic vein recanalization was not feasible or had failed, with a follow-up duration ranging from 7 to 44 months. Based on these cases, intrahepatic collateral vessel recanalization is a promising treatment option in suitable patients with symptomatic BCS and is deserving of further study. Copyright 2010 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20537910     DOI: 10.1016/j.jvir.2010.03.008

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  5 in total

1.  Endovascular treatment for hepatic vein-type Budd-Chiari syndrome: effectiveness and long-term outcome.

Authors:  Zhong-Ke Chen; Jing Fan; Chi Cao; Yu Li
Journal:  Radiol Med       Date:  2018-05-31       Impact factor: 3.469

2.  Accessory hepatic vein recanalization for treatment of Budd-Chiari syndrome due to long-segment obstruction of the hepatic vein: initial clinical experience.

Authors:  Yu Fei Fu; Hao Xu; Ke Zhang; Qing Qiao Zhang; Ning Wei
Journal:  Diagn Interv Radiol       Date:  2015 Mar-Apr       Impact factor: 2.630

3.  Percutaneous recanalization for hepatic vein-type Budd-Chiari syndrome: long-term patency and survival.

Authors:  Yan-Feng Cui; Yu-Fei Fu; De-Chun Li; Hao Xu
Journal:  Hepatol Int       Date:  2015-10-23       Impact factor: 6.047

4.  Percutaneous transluminal angioplasty for symptomatic hepatic vein-type Budd-Chiari syndrome: feasibility and long-term outcomes.

Authors:  Aboelyazid Elkilany; Mohamed Alwarraky; Timm Denecke; Dominik Geisel
Journal:  Sci Rep       Date:  2022-08-18       Impact factor: 4.996

Review 5.  An Update on the Management of Budd-Chiari Syndrome.

Authors:  A Sharma; S N Keshava; A Eapen; E Elias; C E Eapen
Journal:  Dig Dis Sci       Date:  2020-07-20       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.